1. Fourth-Generation Allosteric EGFR Tyrosine Kinase Inhibitors to Combat the Drug Resistance Associated with Non-small Cell Lung Cancer (NSCLC)
   Iqrar Ahmad et al, 2022, Natural Products as Enzyme Inhibitors CrossRef
2. cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway
   Qianwen Zhang et al, 2022, Acta Biochimica et Biophysica Sinica CrossRef
3. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
   Swastika Maity et al, 2020, Pharmacological Reports CrossRef
4. Inhibiting Two Cellular Mutant Epidermal Growth Factor Receptor Tyrosine Kinases By Addressing Computationally Assessed Crystal Ligand Pockets
   Jia-Hau Lee et al, 2019, Future Medicinal Chemistry CrossRef
5. Design, synthesis, anti-cancer evaluation and binding mode studies of benzimidazole/benzoxazole linked β-carboline derivatives
   Reddymasu Sireesha et al, 2021, Journal of Molecular Structure CrossRef
6. Molecular Modeling Studies to Mimic the Binding Hypothesis of NEU3 Sialidase and EGFR in Nonsmall Cell Lung Carcinoma
   Aqsa Khalid et al, 2024, Journal of Computational Biophysics and Chemistry CrossRef